Hock, Emma Stefania http://orcid.org/0000-0002-8617-8875
Martyn-St James, Marrissa http://orcid.org/0000-0002-4679-7831
Wailoo, Allan http://orcid.org/0000-0002-9324-1617
Scott, David L. http://orcid.org/0000-0002-2198-4913
Stevenson, Matt http://orcid.org/0000-0002-3099-9877
Rawdin, Andrew http://orcid.org/0000-0002-1944-458X
Simpson, Emma L. http://orcid.org/0000-0001-7353-5979
Dracup, Naila http://orcid.org/0000-0001-9372-4654
Young, Adam http://orcid.org/0000-0001-5632-9807
Funding for this research was provided by:
Health Technology Assessment Programme (14/17/01)
Programme Grants for Applied Research (RP-PG-0610-10066)
Article History
Accepted: 1 January 2021
First Online: 25 January 2021
Compliance with Ethical Standards
:
: David L. Scott has declared personal fees for advisory board contributions from Baxalta, Novartis UK, and AbbVie, outside the submitted work. No other authors have declared any competing interests.
: This article is a literature review and did not involve any primary research with humans or animals.
: This article is a literature review and did not involve any primary research with humans or animals.
: Not applicable.
: Not applicable.